Eye Cancer (Melanoma and Lymphoma)

+ -Text Size

Other Resources and References TOPICS

References: Eye cancer detailed guide

Albert DM, Kulkarni AD. Intraocular melanoma. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:2090-2098.

American Cancer Society. Cancer Facts & Figures 2014. Atlanta, Ga: American Cancer Society; 2014.

American Joint Committee on Cancer. Malignant melanoma of the uvea. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:547−553.

Carbone M, Ferris LK, Baumann F, et al. BAP1 cancer syndrome: Malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012;10:179.

Carvajal RD, Sosman JA, Quevedo F, et al. Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM). J Clin Oncol. 2013. (suppl; abstr CRA9003).

Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 2008;71:1355-1360.

Grimm SA, Pulido JS, Jahnke K, et al. Primary ocular lymphoma: An International Primary Central Nervous System Lymphoma Collaborative Group report. Ann Oncol. 2007;18:1851-1855.

Harbour JW, Chen R. The DecisionDx-UM gene expression profile test provides risk stratification and individualized patient care in uveal melanoma. PLoS Curr. 2013;Apr 9;5.

Karcioglu ZA, Haik BG. Eye, orbit, and adnexal structures. In: Abeloff MD, Armitage JO, Niederhuber JE. Kastan MB, McKenna WG, eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:1137-1175.

Malignant Melanoma of the Eye. Ocular Oncology Service. Wills Eye Institute, Philadelphia, PA. 2005. Accessed at www.malignantmelanomainfo.com/BG-pages/Mmelanoma-what-is-it.htm on May 18, 2011.

Melia M, Moy CS, Reynolds SM, et al. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS report no. 3. Arch Ophthalmol. 2006;124:226-238.

National Cancer Institute. Physician Data Query (PDQ). Intraocular (Eye) Melanoma: Treatment. 2013. Accessed at www.cancer.gov/cancertopics/pdq/treatment/intraocularmelanoma/healthprofessional on July 24, 2013.

Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Research. 2004;64:7205-7209.

Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191-2199.

Weis E, Shah CP, Lajous M, et al. The association between host susceptibility factors and uveal melanoma: a meta-analysis. Arch Ophthalmol. 2006;124:54-60.

Wu X, Li J, Zhu M, Fletcher JA, Hodi FS. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways. Mol Cancer Ther. 2012;11:1905-1914.

Young JL, Ward KC, Ries LAG. Cancers of rare sites. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, eds. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD, 2007. Accessed at http://seer.cancer.gov/publications/survival on July 22, 2013.

Last Medical Review: 09/13/2013
Last Revised: 02/11/2014